Atezolizumab 840 MG in 14 ML Injection

DRUG2 trials

Sponsors

Palleos Healthcare GmbH, Affimed GmbH

Conditions

Advanced Solid TumorTriple-negative Breast Cancer

Phase 1

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

TerminatedNCT05109442

Affimed GmbHAdvanced Solid Tumor

Start: 2021-11-19End: 2025-06-11Updated: 2025-08-20

Phase 2

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

TerminatedNCT04770272

Palleos Healthcare GmbHTriple-negative Breast Cancer

Start: 2021-03-01End: 2024-10-02Updated: 2026-01-12

Related Papers

Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic <i>EGFR</i> -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.

Journal of Clinical Oncology2025-05-282 citations

Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with <i>EGFR</i> kinase domain mutations ( <i>EGFR</i> mut): Initial results from a phase 2a study.

Journal of Clinical Oncology2025-05-28

Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2024-06-0111 citations

746 AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR<sup>+</sup>) solid tumors: Initial results from the phase 1 dose-escalation study

Regular and Young Investigator Award Abstracts2022-11-01

AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.

Journal of Clinical Oncology2022-06-015 citations